Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia.

Bloch J, Spertini O, Stucki A, Solly F, Blum S.

Leuk Res. 2018 Oct;73:103-104. doi: 10.1016/j.leukres.2018.09.002. Epub 2018 Sep 11. No abstract available.

PMID:
30261456
2.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

Adès L, Thomas X, Guerci Bresler A, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, de Botton S, Lejeune J, Dombret H, Chevret S, Fenaux P; French Belgian Swiss APL group.

Haematologica. 2018 Jul 19. pii: haematol.2018.198614. doi: 10.3324/haematol.2018.198614. [Epub ahead of print]

3.

Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia.

Gavillet M, Spertini O, Blum S.

Leuk Res. 2018 Jun 8;70:87-90. doi: 10.1016/j.leukres.2018.06.004. [Epub ahead of print] No abstract available.

PMID:
29906671
4.

Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy.

Brunel AS, Wójtowicz A, Lamoth F, Spertini O, Neofytos D, Calandra T, Marchetti O, Bochud PY.

Haematologica. 2018 Nov;103(11):e527-e530. doi: 10.3324/haematol.2018.195453. Epub 2018 Jun 7. No abstract available.

5.

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P.

Haematologica. 2018 Nov;103(11):e519-e521. doi: 10.3324/haematol.2018.193151. Epub 2018 May 24. No abstract available.

6.

Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013.

Schnegg-Kaufmann A, Feller A, Baldomero H, Rovo A, Manz MG, Gregor M, Efthymiou A, Bargetzi M, Hess U, Spertini O, Chalandon Y, Passweg JR, Stussi G, Arndt V, Bonadies N; NICER Working Group.

Cancer Epidemiol. 2018 Feb;52:55-62. doi: 10.1016/j.canep.2017.11.008. Epub 2017 Dec 7.

PMID:
29223104
7.

T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance.

Noetzli J, Gavillet M, Masouridi-Levrat S, Duchosal M, Spertini O.

Clin Case Rep. 2017 Jul 3;5(8):1320-1322. doi: 10.1002/ccr3.1032. eCollection 2017 Aug.

8.

Reversible granulocyte abnormalities after accidental ingestion of Colchicum autumnale.

Kritikos A, Spertini O.

Blood. 2017 Jul 6;130(1):95. doi: 10.1182/blood-2017-02-766410. No abstract available.

9.

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Blood. 2017 Mar 23;129(12):1636-1645. doi: 10.1182/blood-2016-10-740613. Epub 2017 Jan 3.

10.

Progressive Organ Failure After Ingestion of Wild Garlic Juice.

Galland-Decker C, Charmoy A, Jolliet P, Spertini O, Hugli O, Pantet O.

J Emerg Med. 2016 Jan;50(1):55-60. doi: 10.1016/j.jemermed.2015.06.034. Epub 2015 Aug 15.

PMID:
26281812
11.

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group.

Cancer. 2015 Jul 15;121(14):2393-9. doi: 10.1002/cncr.29389. Epub 2015 Apr 6.

12.

Using digital RNA counting and flow cytometry to compare mRNA with protein expression in acute leukemias.

Fernandez P, Solenthaler M, Spertini O, Quarroz S, Rovo A, Lovey PY, Leoncini L, Ruault-Jungblut S, D'Asaro M, Schaad O, Docquier M, Descombes P, Matthes T; Swiss Cytometry Society.

PLoS One. 2012;7(11):e49010. doi: 10.1371/journal.pone.0049010. Epub 2012 Nov 9.

13.

Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine.

Gavillet M, Noetzli J, Blum S, Duchosal MA, Spertini O, Lambert JF.

Haematologica. 2012 Dec;97(12):1929-31. doi: 10.3324/haematol.2012.065151. Epub 2012 Aug 8. No abstract available.

14.

Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours.

Boller D, Doepfner KT, De Laurentiis A, Guerreiro AS, Marinov M, Shalaby T, Depledge P, Robson A, Saghir N, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Fattet S, Delattre O, Schweri-Olac A, Höland K, Grotzer MA, Frei K, Spertini O, Waterfield MD, Arcaro A.

Anticancer Res. 2012 Aug;32(8):3015-27.

PMID:
22843869
15.

Ezrin-radixin-moesin-binding sequence of PSGL-1 glycoprotein regulates leukocyte rolling on selectins and activation of extracellular signal-regulated kinases.

Spertini C, Baïsse B, Spertini O.

J Biol Chem. 2012 Mar 23;287(13):10693-702. doi: 10.1074/jbc.M111.318022. Epub 2012 Feb 6.

16.

Chemotherapy is successful in sporadic late onset nemaline myopathy (SLONM) with monoclonal gammopathy.

Novy J, Rosselet A, Spertini O, Lobrinus JA, Pabst T, Kuntzer T.

Muscle Nerve. 2010 Feb;41(2):286-7. doi: 10.1002/mus.21560. No abstract available.

PMID:
19918772
17.

Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib.

Védy D, Muehlematter D, Rausch T, Stalder M, Jotterand M, Spertini O.

J Clin Oncol. 2010 Jan 20;28(3):e33-5. doi: 10.1200/JCO.2009.23.6976. Epub 2009 Nov 9. No abstract available.

PMID:
19901109
18.

P-selectin glycoprotein ligand-1 decameric repeats regulate selectin-dependent rolling under flow conditions.

Tauxe C, Xie X, Joffraud M, Martinez M, Schapira M, Spertini O.

J Biol Chem. 2008 Oct 17;283(42):28536-45. doi: 10.1074/jbc.M802865200. Epub 2008 Aug 19.

19.

Management of an acute coronary syndrome in a patient with severe haemophilia A.

Ferrario C, Renders F, Cairoli A, Vuffray A, Spertini O, Angelillo-Scherrer A.

Haemophilia. 2007 Nov;13(6):763-5. Review. No abstract available.

PMID:
17973854
20.

Evolutionary conservation of P-selectin glycoprotein ligand-1 primary structure and function.

Baïsse B, Galisson F, Giraud S, Schapira M, Spertini O.

BMC Evol Biol. 2007 Sep 14;7:166.

21.
22.

Lipid raft adhesion receptors and Syk regulate selectin-dependent rolling under flow conditions.

Abbal C, Lambelet M, Bertaggia D, Gerbex C, Martinez M, Arcaro A, Schapira M, Spertini O.

Blood. 2006 Nov 15;108(10):3352-9. Epub 2006 Jul 18.

23.

Dermatomyositis, lobar panniculitis and inflammatory myopathy with abundant macrophages.

Carrera E, Lobrinus JA, Spertini O, Gherardi RK, Kuntzer T.

Neuromuscul Disord. 2006 Jul;16(7):468-71. Epub 2006 Jun 30.

PMID:
16809038
24.

Images in clinical medicine. Spurious platelet count.

Siegenthaler M, Spertini O.

N Engl J Med. 2006 May 4;354(18):1936. No abstract available.

25.

Eosinophilic perimyositis as the presenting feature of a monoclonal T-cell expansion.

Dunand M, Lobrinus JA, Spertini O, Kuntzer T.

Muscle Nerve. 2005 May;31(5):646-51.

PMID:
15770667
26.

Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role of human fucosyltransferase-IV and -VII.

Martinez M, Joffraud M, Giraud S, Baïsse B, Bernimoulin MP, Schapira M, Spertini O.

J Biol Chem. 2005 Feb 18;280(7):5378-90. Epub 2004 Dec 3. Erratum in: J Biol Chem. 2005 Apr 15;280(15):15483.

27.

A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation.

Hauert J, Fernandez-Carneado J, Michielin O, Mathieu S, Grell D, Schapira M, Spertini O, Mutter M, Tuchscherer G, Kovacsovics T.

Chembiochem. 2004 Jun 7;5(6):856-64.

PMID:
15174170
28.

NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC.

Silva AP, Cavadas C, Baïsse-Agushi B, Spertini O, Brunner HR, Grouzmann E.

Regul Pept. 2003 Nov 15;116(1-3):71-9.

PMID:
14599717
29.

Molecular basis of leukocyte rolling on PSGL-1. Predominant role of core-2 O-glycans and of tyrosine sulfate residue 51.

Bernimoulin MP, Zeng XL, Abbal C, Giraud S, Martinez M, Michielin O, Schapira M, Spertini O.

J Biol Chem. 2003 Jan 3;278(1):37-47. Epub 2002 Oct 25.

30.

Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination.

Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O.

Blood. 2001 Apr 1;97(7):2121-9.

31.
32.

Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin.

André P, Spertini O, Guia S, Rihet P, Dignat-George F, Brailly H, Sampol J, Anderson PJ, Vivier E.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3400-5.

33.

Elastase and metalloproteinase activities regulate soluble complement receptor 1 release.

Sadallah S, Hess C, Miot S, Spertini O, Lutz H, Schifferli JA.

Eur J Immunol. 1999 Nov;29(11):3754-61.

34.

Soluble complement receptor 1 is increased in patients with leukemia and after administration of granulocyte colony-stimulating factor.

Sadallah S, Lach E, Schwarz S, Gratwohl A, Spertini O, Schifferli JA.

J Leukoc Biol. 1999 Jan;65(1):94-101.

PMID:
9886251
35.

Relationship between cleaved L-selectin levels and the outcome of acute myeloid leukemia.

Extermann M, Bacchi M, Monai N, Fopp M, Fey M, Tichelli A, Schapira M, Spertini O.

Blood. 1998 Nov 1;92(9):3115-22.

38.

Monocyte adhesion to activated aortic endothelium: role of L-selectin and heparan sulfate proteoglycans.

Giuffrè L, Cordey AS, Monai N, Tardy Y, Schapira M, Spertini O.

J Cell Biol. 1997 Feb 24;136(4):945-56.

39.
40.

[Regulation of leukocyte migration by adhesion molecules].

Spertini O.

Schweiz Med Wochenschr. 1996 Nov 9;126(45):1926-34. Review. French.

PMID:
8992620
41.
42.

Cleaved L-selectin concentrations in meningeal leukaemia.

Stucki A, Cordey AS, Monai N, de Flaugergues JC, Schapira M, Spertini O.

Lancet. 1995 Feb 4;345(8945):286-9.

PMID:
7530792
43.

High levels of the shed form of L-selectin are present in patients with acute leukemia and inhibit blast cell adhesion to activated endothelium.

Spertini O, Callegari P, Cordey AS, Hauert J, Joggi J, von Fliedner V, Schapira M.

Blood. 1994 Aug 15;84(4):1249-56.

44.

ELISA for quantitation of L-selectin shed from leukocytes in vivo.

Spertini O, Schleiffenbaum B, White-Owen C, Ruiz P Jr, Tedder TF.

J Immunol Methods. 1992 Nov 25;156(1):115-23.

PMID:
1385536
45.

Neutrophils, monocytes, and lymphocytes bind to cytokine-activated kidney glomerular endothelial cells through L-selectin (LAM-1) in vitro.

Brady HR, Spertini O, Jimenez W, Brenner BM, Marsden PA, Tedder TF.

J Immunol. 1992 Oct 1;149(7):2437-44.

PMID:
1382103
46.

Soluble L-selectin is present in human plasma at high levels and retains functional activity.

Schleiffenbaum B, Spertini O, Tedder TF.

J Cell Biol. 1992 Oct;119(1):229-38.

47.
48.

Tissue-specific migration pathways by phenotypically distinct subpopulations of memory T cells.

Mackay CR, Marston WL, Dudler L, Spertini O, Tedder TF, Hein WR.

Eur J Immunol. 1992 Apr;22(4):887-95.

PMID:
1372559
49.

Reaction of acetaldehyde with human platelets.

Spertini O, Hauert J, Bachmann F.

Thromb Haemost. 1992 Jan 23;67(1):126-30.

PMID:
1615467
50.

Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion.

Spertini O, Luscinskas FW, Kansas GS, Munro JM, Griffin JD, Gimbrone MA Jr, Tedder TF.

J Immunol. 1991 Oct 15;147(8):2565-73.

PMID:
1717567

Supplemental Content

Loading ...
Support Center